Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tianjin Biopharmaceutical Innovation Park To Start Operation In April

This article was originally published in PharmAsia News

Executive Summary

China's biopharmaceutical international innovation park, sited in Tianjin Economic-Technological Development Area, has completed its phase one construction and will go into operation in April. To date, the park has received more than 170 domestic and overseas applications of R&D projects; it has already confirmed the location of four industrial companies with investment of over RMB100 million ($14.61 million) each. Tianjin International Biomedical Research Institute, the park's core component, will by year end establish a series of technical platforms including its clinical trial center, drug analysis and testing center, and information center. By the end of 2010, the park will be a world-class biopharmaceutical R&D base with more than 100 R&D teams and 1,000 people. (Click here for more - Chinese Language)

You may also be interested in...



Seretide Settlement To Lift Glenmark’s Europe Business

Glenmark can sell its partnered generic rival to GSK’s Seretide Accuhaler dry powder inhaler in certain European markets following a settlement with the UK company. The Indian firm has also shelved divestment plans for its API business, at least for now.

US/India Operation Intercepts Unapproved Drugs, Drug/Device Products

Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.

Two Companies, Two BARDA Contracts, Two Approaches To Coronavirus

Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.

UsernamePublicRestriction

Register

SC070991

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel